



(43) International Publication Date
19 July 2012 (19.07.2012)

(10) International Publication Number
WO 2012/097270 A1

- (51) **International Patent Classification:**
C07D 407/04 (2006.01) *A61K 31/506* (2006.01)
- (21) **International Application Number:**
PCT/US2012/021275
- (22) **International Filing Date:**
13 January 2012 (13.01.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/433,161 14 January 2011 (14.01.2011) US
- (71) **Applicant (for all designated States except US):** VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 130 Waverly Street, Cambridge, MA 02139 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** SHANNON, Dean [CA/US]; 19 Stonnybrook Lane, Milford, MA 01757 (US). LUISI, Brian [US/US]; 15 Gibbens Treet, Somerville, MA 02143 (US). LIAO, Yusheng [US/US]; 54 Spring Street, Lexington, MA 02421 (US). KRAWIEC, Mariusz [PL/US]; 46 Littlefield Lane, Marlborough, MA 01752 (US).
- (74) **Agent:** BOUDREAUX, William, R.; Brinks Hofer Gilson & Lione, 524 South Main Street, Suite 200, Ann Arbor, MI 48104 (US).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) **Title:** SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-{1-HYDROXY-1-METHYL-ETHYL}PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)}-1H-BENZIMIDAZOL-2-YL]UREA

(57) **Abstract:** The present application is directed to solid forms of compounds of formula (I); and pharmaceutically acceptable salts thereof, that inhibit bacterial gyrase and/or Topo IV and pharmaceutical compositions comprising said compounds and salts. These compounds and salts are useful in treating bacterial infection.



WO 2012/097270 A1